BioRestorative Therapies Announces Reverse Stock Split
BioRestorative will implement a 1-for-20 reverse split to consolidate shares and target continued Nasdaq Capital Market listing.
Rhea-AI Summary
BioRestorative Therapies (BRTX) approved a 1-for-20 reverse stock split of its common stock, with the change effective as of 4:30 p.m. Eastern Time on September 7, 2026. The stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market on September 8, 2026, under symbol BRTX and new CUSIP 090655705.
The split is intended to help the company regain compliance with Nasdaq’s $1.00 minimum bid price requirement. Outstanding common shares will be reduced from 27,622,556 as of August 28, 2026, to approximately 1,381,128, and authorized shares will decrease proportionately from 1,500,000,000 to 75,000,000. Each twenty shares will convert into one share with unchanged par value, and ownership percentages are expected to remain the same except for fractional share rounding, where holders will receive one whole share rounded up.
Positive
- 1-for-20 reverse stock split reduces outstanding shares from 27,622,556 to approximately 1,381,128
- Authorized common shares cut from 1,500,000,000 to 75,000,000, aligning capital structure with the new share count
- Reverse split is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing
- Fractional shares will be rounded up so each affected holder receives one whole share of common stock
Negative
- Company must execute a reverse split to address Nasdaq’s $1.00 minimum bid price requirement for continued listing
News Explained
Beyond converting common shares, the reverse split will proportionally adjust outstanding options, warrants, other incentive awards, their exercise prices, and shares reserved under the 2021 plan.
Market reaction after 1-for-20 reverse stock split: BRTX -12.79%
Following this news, BRTX has declined 12.79%, reflecting a significant negative market reaction. Argus tracked a trough of -11.1% from its starting point during tracking. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.18. Trading volume is above average at 1.6x the average, suggesting increased trading activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Clinical manufacturing | Positive | -0.8% | Completed BRTX-100 Phase 2 clinical supply manufacturing |
| Jun 18 | Leadership appointment | Positive | +2.5% | Appointed healthcare executive to lead Biocosmeceuticals expansion |
| May 27 | Stake acquisition | Positive | +73.3% | Investor acquired a 4.9% stake through open-market purchases |
| May 26 | Clinical trial update | Positive | +20.1% | Completed Phase 2 dosing in a 99-patient BRTX-100 trial |
| May 13 | Preclinical data | Positive | -5.8% | Presented preclinical exosome functionality data at ISCT 2026 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive announcements produced mixed reactions, with three positive moves and two negative moves.
Key Terms
reverse stock split financial
cusip number technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Reverse Stock Split under Nevada law. The Company filed a certificate of change with the Secretary of State of the State of Nevada, which is expected to become effective as of 4:30 P.M. Eastern Time on September 7, 2026. The Common Stock will begin trading on The Nasdaq Capital Market on a reverse split-adjusted basis at the start of trading on September 8, 2026, under the symbol “BRTX” and under a new CUSIP number, 090655705. The Company is effecting the Reverse Stock Split with the intention of regaining compliance with the
Upon implementation of the Reverse Stock Split, every twenty shares of the Company’s issued and outstanding Common Stock will automatically convert into one share of Common Stock without any change to the par value of
No fractional shares of Common Stock will be issued in connection with the Reverse Stock Split. Instead, each holder of record who would otherwise be entitled to receive a fractional share will receive one whole share of Common Stock, rounded up to the nearest whole share. Stockholders holding shares in street name through a bank, broker, or other nominee will have their positions adjusted in accordance with the procedures of such bank, broker, or nominee.
Information for Stockholders
TranShare Corporation, the Company’s transfer agent, will send instructions to stockholders of record who hold stock certificates regarding the exchange of certificates for Common Stock. Stockholders who hold their shares of Common Stock in book-entry form or in brokerage accounts or “street name” are not required to take any action to effect the exchange of their shares of Common Stock following the Reverse Stock Split.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs relate to the treatment of disc/spine disease (our lead cell therapy candidate, BRTX-100, is currently in a Phase 2 clinical trial for the treatment of chronic lumbar disc disease) and metabolic disorders (our ThermoStem® Program). We have also developed a commercial biocosmeceutical platform through which we formulate, manufacture and sell cell-based biologic aesthetic products.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are intended to qualify for the protection of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “targets,” “will,” “would,” and similar expressions, and the negatives of those terms. Forward-looking statements in this press release include, among others, statements regarding the timing and effectiveness of the Reverse Stock Split and the anticipated market-effective and first-trading dates; the anticipated post-split trading price of the Common Stock and the ability of the Reverse Stock Split to result in a sustained increase in the price of the Common Stock to a level at or above
These forward-looking statements are based on the Company’s current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the Reverse Stock Split does not result in a sustained increase in the price of the Common Stock, or that the price of the Common Stock subsequently declines below
Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by applicable law. You should not place undue reliance on these forward-looking statements.
Investor Contact:
Rory Rumore
Investor Relations
investors@biorestorative.com
